Archives
-
Firefly Luciferase mRNA for LNP Assay Design
2026-10-01
Firefly Luciferase mRNA can function as more than a bright reporter: it can reveal how formulation composition and manufacturing process shape biological performance. This guide applies 5-moUTP modified mRNA to rigorous LNP screening, translation analysis, and assay interpretation.
-
D-Luciferin Potassium Salt for Translational BLI
2026-09-30
Use D-Luciferin potassium salt to convert luciferase expression into a longitudinal readout for tumor cell tracking, treatment response, and reporter biology. This practical guide connects substrate preparation and imaging controls with a probiotic-guided colorectal cancer study, while emphasizing assay limits and troubleshooting.
-
EZ Cap™ Firefly Luciferase mRNA Guide
2026-09-30
EZ Cap™ Firefly Luciferase mRNA (m1Ψ) is a capped, polyadenylated reporter transcript for transient firefly luciferase expression. Its Cap1 structure, m1Ψ nucleotides, and approximately 100-nucleotide poly(A) tail are designed to support translation, stability, and lower innate immune activation.
-
FLNa–NF-κB Control of Hepatitis E Virus Replication
2026-09-29
Xia and colleagues identify filamin A (FLNa) as a cytoskeletal regulator that connects HEV infection with NF-κB signaling, apoptosis, and inflammatory responses. Across patient, animal, and cell-culture models, reduced FLNa impaired IκB degradation and NF-κB nuclear translocation, creating conditions that favored viral replication and particle release.
-
Ciprofloxacin, Zinc, and RSL3-Induced Ferroptosis
2026-09-29
The reference study shows that ciprofloxacin can enhance, rather than suppress, ferroptosis when paired with RSL3 by driving mitochondrial Zn2+ accumulation through a STING1–CAV2 signaling route. Its findings clarify why ciprofloxacin has stimulus-dependent effects on regulated cell death and identify ATP-based viability measurement as a useful phenotypic endpoint, but not a standalone mechanistic proof.
-
MK-8745: Aurora A Biology to Translational Evidence
2026-09-28
MK-8745 provides a practical way to test whether elevated Aurora A is merely a tumor feature or a functional dependency. By connecting mitotic arrest, genotype-aware apoptosis, retinoblastoma pathology, lymphoma models, and xenograft response, researchers can build a more decision-ready translational evidence package.
-
Palonosetron in Chemotherapy-Induced Nausea Prevention
2026-09-28
Ruhlmann and Herrstedt review palonosetron’s distinctive 5-HT3-receptor pharmacology and the clinical evidence for preventing chemotherapy-induced nausea and vomiting (CINV), with particular attention to delayed symptoms. Their central message is that pharmacologic differences matter only when they translate into meaningful clinical outcomes, and that palonosetron should be assessed within combination antiemetic regimens and across separate acute and delayed windows.
-
Firefly Luciferase mRNA: Workflow & LNP Insights
2026-09-27
Build a sensitive, interpretable luciferase readout with Cap1-capped, 5-moUTP modified mRNA—and separate delivery performance from cell health and assay chemistry. A recent cryogenic mass-spectrometry study adds a useful LNP design perspective, while a practical pilot workflow helps researchers optimize transfection without treating one dose as universal.
-
β-Galactosidase Reporter Assay Kit for Promoter Studies
2026-09-26
A β-galactosidase reporter assay can turn promoter activity into a measurable enzyme readout, but the signal reflects more than transcription alone. This guide connects assay design and interpretation to new work on modular promoters that function in both Escherichia coli and Saccharomyces cerevisiae.
-
JC-1 Assay in Cancer Immunomodulation
2026-09-25
Explore how a mitochondrial membrane potential assay can sharpen interpretation of cancer immunomodulator studies. This article connects JC-1 readouts with recent TrxR/MAPK findings while clarifying what mitochondrial depolarization can—and cannot—prove.
-
Rhamnolipid LNPs Target Dendritic Cells in mRNA Vaccines
2026-09-25
This study replaces PEG-lipids in mRNA lipid nanoparticles with microbial rhamnolipids, combining particle stabilization with immune stimulation. The resulting particles showed dendritic-cell-associated uptake, lymph-node-directed expression, and stronger vaccine responses than size-matched PEG-LNPs, while avoiding a reported PEG-associated mast-cell response during repeat dosing.
-
HCMV UL38 Destabilizes IRS1 to Attenuate AKT
2026-09-24
The study links the HCMV protein UL38 to reduced serum responsiveness of AKT, identifying mTORC1-dependent IRS1 destabilization as the proposed mechanism. Its combination of viral loss-of-function, UL38 expression, and pathway-inhibition experiments supports a cell-intrinsic feedback model, while leaving questions about mechanism and relevance across infection settings for future work.
-
DOTAP Workflows for Functional Genomics
2026-09-24
Use DOTAP to build a tunable starting point for plasmid, RNA, and oligonucleotide delivery—then optimize the lipid-to-cargo ratio for your cell model instead of assuming one formulation fits all. A recent immunometabolism study offers a useful design lesson about targeted delivery, while not testing DOTAP itself.
-
Measuring Ferroptosis Beyond a Single Viability Number
2026-09-23
A ferroptosis experiment can show a compelling mechanistic story and still leave a central question unanswered: did the treatment reduce viable cells? This article connects recent findings on ciprofloxacin–RSL3 responses to practical ATP-based cell viability measurement, explaining where luminescence adds value, where it can mislead, and how to build stronger translational evidence.
-
AP20187 for Conditional Cell Signaling
2026-09-23
AP20187 is a chemical inducer of dimerization for temporally controlled fusion-protein signaling, reporter activation, regulated cell therapy, and metabolic research. This workflow-focused guide also shows how to adapt the platform to stromal–immune assays inspired by senescent CAF research without overstating what the reference study demonstrated.